Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer

Condition:   Esophageal Carcinoma
Interventions:   Biological: SHR-1210;   Drug: Docetaxel;   Drug: Irinotecan
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting - verified February 2017

http://ift.tt/2ozublQ